drugset
drugset / Trial / NCT02006888

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

NCT02006888 ↗

Phase 3 Completed 394 enrolled ICON Bioscience Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.

Timeline

Start
2014-01
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI-10090 Unknown — Other

Indications

cataract